Latest news with #dietarySupplements
Yahoo
23-05-2025
- Business
- Yahoo
Safe Shot to Capitalize on Yerbae's Strong Retail Presence & Distributor Network Following Acquisition
Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024 SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ('SHOT', "Safety Shot', or the 'Company'), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. ('Yerbae') after its recently announced acquisition of the company. With Yerbae's momentum into 2025, Safety Shot expects to leverage the brand's expanding retail presence, strong distributor network, and innovative product portfolio to accelerate growth and strengthen its market position. In addition, the Company anticipates a 1000% increase in 2025 annual revenue over 2024 following the acquisition, bringing significant additional shareholder value. 'Yerbae's outstanding performance and proven track record in key markets offer Safety Shot a unique opportunity to scale our operations, expand our retail reach and capitalize on new opportunities while increasing revenue right out of the gate,' said Jarrett Boon, Safety Shot CEO. 'This acquisition not only enhances our portfolio but also solidifies our commitment to delivering innovative health and wellness solutions to consumers nationwide.' Yerbae's extraordinary success in 2024 has laid the groundwork for a strong 2025, and Safety Shot is poised to build on this momentum. With Yerbae's market expertise and Safe Shot's strategic vision, the combined companies are set to redefine the landscape of functional beverages. Yerbaé's retail successes provide additional retail opportunities for Safety Shot, and include: 1. North America's Largest Club Store Retailer: Yerbae has become a regional favorite since its 2022 launch, showcasing dominant performance and growth. The southwest division of North America's largest club store retailer, which spans across six states, emphasized Yerbae as part of its 'Back to Health' initiative in Q1 2025. Based on strong Q1 performance, Yerbae expects to continue this partnership through the second half of 2025.2. Kroger Expansion: Kroger, North America's largest grocery retailer, authorized Yerbae in over 1,200 locations across 22 states, featuring eight divisions: ● Fred Meyer (OR, WA, ID) ● Smith's (UT, ID, MT, WY) ● Fry's (AZ) ● King Soopers (CO, WY) ● Kroger Cincinnati (OH) ● Kroger Atlanta (GA, AL, SC) ● Kroger Houston Region ● Kroger Dallas Region Yerbae expects to see massive upside at Kroger in 2025, as its distribution began ramping up in late 2024. Kroger's Natural Sales Event in January 2025 will further amplify Yerbae's presence, with major placements in Kroger Cincinnati, Smith's, and King Soopers. These regions are showcasing Yerbae products at upward of 80% division ACV, expanding placement to three points of distribution across each region. 3. Sprouts Farmers Market: After a stellar year with +45.2% dollar growth1, Sprouts is expanding Yerbae's portfolio with a new SKU, across 419 stores, including dry and cold placements.4. Casey's General Stores: Following Yerbae's dominant national expansions through Club Retail, Natural and Grocery and its emerging presence amongst better for you consumers, Casey's General Stores authorized Yerbae into 300 of its Midwest based convenience locations including its cold innovation sets. Programming is expected to launch in September of 2025.5. Other Retail Highlights: ● Mariano's & Pick 'n Save: Executed Splash displays mid-Q1 2025 across 107 stores (IL, WI). ● Jewel Osco: Focus brand placement with three new SKUs in 75 stores. ● Ahold Delhaize Banners: Continued growth with Stop & Shop and Giant Foods expanding 16oz authorizations. Distribution Network Expansion With Yerbae's retail success comes distribution growth. Key partnerships include: ● Anheuser Busch Distributors: Wisconsin Distributors, Resort Beverage, Penn Beer, Alber & Leff, Wilsbach Distributing (PA), and Maverick Distributing (NE, IA). ● Molson Coors Distributors: Stagnaro Distributing (OH) and Southeast Beverage (OH). ● Other Notable Partners: Savannah Distributing (GA), Grey Eagle Distributing (MO), Crescent Crown Distributing (AZ), KeHE Dallas, Carlson Distributing (UT), and more. Yerbae's collaboration with DP Distributing has expanded to Caribbean and West Coast ports, including Long Beach, San Diego, and Seattle, fueling growth in cruise ship and resort markets. While the Company does not expect to expand Safety Shot into the Food Service category, Yerbae's food service partnerships bring its products directly to consumers in diverse settings, which will continue to expand the reach of the combined entity. These include: ● Guckenheimer: Yerbae products are now available in over 340 national accounts, including Google, Spotify, and Paramount. ● Evergreen Vending: Expanded Yerbae's reach to over 900 micro markets, including Amazon, Boeing, and Alaska Airlines and expanding over Pacific Northwest, Inner Mountain and Rocky Mountain regions. ● Vistar: Secured placements in LinkedIn's Bellevue, WA office. ● Bon Appétit: Added Yerbae SKUs in West Coast accounts, including Docusign and Uber. ● Compass USA: Expanded Yerbae's footprint to Rivian's facilities in Normal, IL. About Safety Shot, Inc. Safety Shot, Inc., a wellness and dietary supplement company, has developed Sure Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Sure Shot is available for purchase online at and Amazon. The Company is introducing business-to-business sales of Sure Shot to distributors, retailers, restaurants, and bars throughout 2025. Yerbaé Brands Corp. Founded in 2017 by Todd Gibson and Karrie Gibson, Yerbaé Brands Corp., (TSX-V: YERB.U; OTCQX: YERBF) is disrupting the energy beverage marketplace with great tasting, zero sugar, zero calorie beverages, while using plant-based ingredients that are designed to meet the needs of the wellness forward consumer. Harnessing the power of nature, Yerbaé's key ingredient (yerba mate, a South American herb) is known to produce 196 different vitamins, minerals and nutrients as well as caffeine. By combining yerba mate with its premium ingredients and flavors, Yerbaé provides consumers with a no compromise energy solution. All Yerbaé energy beverages are zero calorie, zero sugar, non-GMO, and gluten free. Find us @DrinkYerbaé on Instagram, Facebook, Twitter and TikTok, or online at Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed business combination between SHOT and Yerbaé. All statements other than statements of historical facts contained in this press release, including statements regarding Pubco's, SHOT' or Yerbaé's future results of operations and financial position, Pubco's, SHOT' and Yerbaé's business strategy, prospective costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated operations of Pubco, SHOT and Yerbaé, and the expected value of the combined company after the transactions, are forward-looking statements. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the following risks relating to the proposed business combination: the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of SHOT' securities; the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement; the inability to complete the transactions contemplated by the definitive agreement, including due to failure to obtain approval of the shareholders of SHOT or other conditions to closing in the definitive agreement; the inability to obtain or maintain the listing of SHOT ordinary shares on Nasdaq following the business combination; the risk that the transactions contemplated by the business combination disrupt current plans and operations of SHOT as a result of the announcement and consummation of these transactions; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth economically and hire and retain key employees; costs related to the business combination; changes in applicable laws or regulations; the possibility that Yerbaé or SHOT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the Registration Statement and accompanying proxy statement/prospectus (when available) relating to the transactions, including those under 'Risk Factors' therein, and in other filings with the SEC made by SHOT. Moreover, Yerbaé and SHOT operate in very competitive and rapidly changing environments. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Yerbaé's and SHOT' control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. None of Yerbaé or SHOT gives any assurance that either Yerbaé or SHOT will achieve its expectations. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Yerbaé and SHOT assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Investor RelationsMedon MichaelidesPhone: 561-244-7100Email: investors@ 1 SPINS, Latest 52 Weeks, Period Ending Dec, 16, 2024Sign in to access your portfolio
RNZ News
10-05-2025
- Health
- RNZ News
Cinnamon could interact with some prescription medications, study finds
By Katla Hetter, of CNN The study was clear that small amounts of cinnamon such as in food like these cinnamon apples or on hot drinks does not put people at risk of overconsumption. Photo: Jenny Garing While cinnamon is a popular spice added to many foods, it has a long history of uses in traditional medicine in many cultures. Today, cinnamon products are sold as dietary supplements to help with a variety of health conditions, including treating diabetes, promoting weight loss and relieving hay fever and other inflammatory conditions. But how much is too much cinnamon? Could there be negative impacts from overconsumption of cinnamon products? People should be cautious because cinnamon could affect the metabolism of prescription drugs, according to a study published in the journal Food Chemistry: Molecular Sciences . The authors warned against overconsumption of cinnamon-containing substances, especially in individuals with other health conditions. To help us make sense of the study findings and what the major takeaways are for cinnamon consumption, I spoke with CNN wellness expert Dr Leana Wen, an emergency physician and adjunct associate professor at George Washington University. She previously served as Baltimore's health commissioner. Wen: Cinnamon is a spice that comes from the dried bark of Cinnamomum trees. The most common type of cinnamon sold in North America is Cassia cinnamon from the Cinnamomum aromaticum trees, according to the National Center for Complementary and Integrative Health, which is one of the centers under the National Institutes of Health. Ceylon cinnamon, sometimes called "true" cinnamon, is from Cinnamomum verum trees. Though some studies have suggested that cinnamon supplementation could be helpful for diabetes treatment or for weight loss, more research is needed to investigate the benefits. Similarly, though preliminary research points to a possible role of nasal spray with Ceylon cinnamon as helping with allergic rhinitis, more research is needed to confirm that it could be a treatment. The National Center for Complementary and Integrative Health states that "research doesn't clearly support using cinnamon for any health condition". Cinnamon is not approved by the US Food and Drug Administration (FDA) for the treatment of any medical condition. Wen: Cassia cinnamon may contain high levels of coumarin, which is a blood thinner. Ceylon cinnamon may also have trace amounts of coumarin. If someone who is already on anticoagulant medications ingests a large amount of coumarin, this could increase their bleeding risk. In addition, there are known interactions between coumarin and the liver. Prolonged use of cinnamon products that have high coumarin content could pose health risks for people with liver disease. Moreover, the National Center for Complementary and Integrative Health states there are "theoretical reasons" to think there may be interactions between cinnamon and anti-cancer medications and nicotine. Wen: This new study examined the primary active ingredient of cinnamon, which is called cinnamaldehyde. Researchers first looked at whether cinnamaldehyde is well absorbed when orally ingested by examining gastric and intestinal fluids. They found that it is 100 percent bioaccessible in both fluids that are fasted and fed. That means that whether someone is fasting or has just eaten, cinnamaldehyde is expected to be well absorbed. They then discovered that cinnamaldehyde is rapidly metabolised into another compound, cinnamic acid, and that it can activate multiple receptors that affect drug metabolism. The possible interference with drug metabolism is what led the authors to conclude that overconsumption could induce herb-drug interactions. They urge additional research looking into these possible interactions. Until those studies are complete, as the researchers indicated in an associated news release, they recommend that people looking to take cinnamon as a dietary supplement exercise caution and consult a physician before using. Wen: According to the study's researchers, the list of chronic conditions that should prompt caution before trying cinnamon supplementation includes hypertension, diabetes, cancer, arthritis, asthma, obesity, HIV/AIDS and depression. I would add to that list anyone using blood thinner medications - for example, someone who has a history of heart disease and stroke, any medications that are cleared through the liver, and other dietary supplements that may interact with cinnamon, including turmeric, ginseng and gingko biloba. Wen: The researchers are quite clear that a sprinkling of cinnamon for typical culinary use is unlikely to cause problems. What they warn against is what they refer to as "overconsumption". This isn't clearly defined, as their study was not set up to examine what could be too high of a level of cinnamon. What overconsumption probably refers to is using concentrated cinnamon products like cinnamon supplements over a prolonged period - for instance, taking cinnamon capsules every day for months. Individuals who are thinking of taking cinnamon supplements should be sure to consult their health care providers to check for possible medication interactions. They should also be aware that there's no clear evidence for the benefit of cinnamon supplementation. Wen: Consumers should know that the FDA does not regulate dietary supplements like they do prescription medications. Under current law, the FDA does not have the authority to regulate the efficacy of dietary supplements. The FDA also does not review supplements before they go to market. Instead, the agency relies on post-market surveillance to identify safety problems. People should be cautious about taking dietary supplements. Just because something is marketed as being "natural" doesn't mean that it is safe. Also, something that is safe in small quantities may become unsafe in large quantities. People should always mention what supplements they are taking or thinking of taking to their healthcare provider to assess for drug interactions. - CNN
